Denali Therapeutics (DNLI) EPS (Weighted Average and Diluted) (2018 - 2024)
Historic EPS (Weighted Average and Diluted) for Denali Therapeutics (DNLI) over the last 7 years, with Q4 2024 value amounting to -$0.7.
- Denali Therapeutics' EPS (Weighted Average and Diluted) rose 1985.24% to -$0.7 in Q4 2024 from the same period last year, while for Sep 2025 it was -$0.67, marking a year-over-year increase of 7363.39%. This contributed to the annual value of -$2.57 for FY2024, which is 14249.61% down from last year.
- Latest data reveals that Denali Therapeutics reported EPS (Weighted Average and Diluted) of -$0.7 as of Q4 2024, which was up 1985.24% from -$0.63 recorded in Q3 2024.
- Denali Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $2.28 for Q4 2020, and its period low was -$0.87 during Q4 2023.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.6 (2021), whereas its average is -$0.4.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 50349.23% in 2020, then crashed by 14511.83% in 2024.
- Over the past 5 years, Denali Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $2.28 in 2020, then crashed by 127.19% to -$0.62 in 2021, then dropped by 20.97% to -$0.75 in 2022, then decreased by 16.0% to -$0.87 in 2023, then rose by 19.85% to -$0.7 in 2024.
- Its EPS (Weighted Average and Diluted) stands at -$0.7 for Q4 2024, versus -$0.63 for Q3 2024 and -$0.59 for Q2 2024.